(Abst.) Efficacy of rituximab in refractory RRMS on: May 04, 2018, 02:21:14 pm #1 This French study concerns a group of RRMS patients who had continued to progress in spite of taking natalizumab (Tysabri), mitoxantrone (Novantrone) or fingolimod (Gilenya) and who were given rituximab (Rituxan).From PubMed, May 4, 2018: Efficacy of rituximab in refractory RRMS - PubMed This study provides level IV evidence that rituximab reduces clinical and MRI disease activity in patients with active RRMS despite immunosuppressive DMT. PubMed · ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
